These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 32602076)
1. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series. Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076 [TBL] [Abstract][Full Text] [Related]
2. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995 [TBL] [Abstract][Full Text] [Related]
3. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208 [TBL] [Abstract][Full Text] [Related]
4. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730 [TBL] [Abstract][Full Text] [Related]
5. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446 [TBL] [Abstract][Full Text] [Related]
6. PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study. Francolini G; Banini M; Di Cataldo V; Detti B; Caini S; Loi M; Simontacchi G; Desideri I; Greto D; Valzano M; Roghi M; Serni S; Vaggelli L; Salvestrini V; Visani L; Becherini C; Olmetto E; Franzese C; Baldaccini D; Scorsetti M; Sollini M; Chiti A; Meattini I; Valicenti RK; Livi L Prostate; 2023 Sep; 83(12):1201-1206. PubMed ID: 37290915 [TBL] [Abstract][Full Text] [Related]
7. Patterns of relapse as determined by Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231 [TBL] [Abstract][Full Text] [Related]
8. A Multicenter Prospective Clinical Trial of McCarthy M; Francis R; Tang C; Watts J; Campbell A Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448 [TBL] [Abstract][Full Text] [Related]
9. von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [TBL] [Abstract][Full Text] [Related]
10. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy. Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
12. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients. Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603 [TBL] [Abstract][Full Text] [Related]
13. The use of Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440 [TBL] [Abstract][Full Text] [Related]
17. Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600 [TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
19. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521 [TBL] [Abstract][Full Text] [Related]
20. The role of ( Yilmaz U; Komek H; Can C; Altindag S Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]